The purpose of this training program is to prepare postdoctoral researchers for careers in immunologic research that will enable them to have a significant impact on the prevention, diagnosis and treatment of cancer. Over the past decade the field of immunology has witnessed an unprecedented level of discovery on every front. These exciting advances have led to an improved understanding of how cancers evade the immune system and how innate and specific immunity can be manipulated in order to generate an anti-tumor immune response. In order to translate this new knowledge into effective treatments for cancer, it will be necessary to train a new generation of immunologists who are well-versed in the most recent concepts in tumor immunology. Trainees will engage in an intensive program of immunologic research under the guidance of an accomplished mentor with expertise in a specific area of immunology. This will permit the young investigator to develop a focused immunologic research question and relate it to important clinical and scientific problems. In order that they understand the most important issues facing the modern oncologist, trainees will participate in a carefully designed program of courses, conferences, and meetings sponsored by the Ohio State University Comprehensive Cancer Center and its Immunology Program. These trainees will also benefit from significant exposure to related disciplines such as bioinformatics, human cancer genetics, translational medicine, and experimental therapeutics, as well as training in the responsible conduct of human research. This additional instruction will help trainees to understand the translational potential of their discoveries. This program will encourage the participation of both physician-scientists and trainees with a basic science background in order to enhance the exchange of ideas, stimulate intellectual curiosity, and broaden the perspectives of the participants. Similarly, there will be a concerted effort to recruit minority individuals and persons from disadvantaged backgrounds into this program. Successful completion of this training program will foster the development of the trainee's research skills and scientific expertise in preparation for an immunologic research career that will have a positive impact on the health needs of our nation's cancer patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
Schools of Medicine
United States
Zip Code
Mansfield, Sara; Dwivedi, Varun; Byrd, Sara et al. (2016) Broncholaveolar lavage to detect cytomegalovirus infection, latency, and reactivation in immune competent hosts. J Med Virol 88:1408-16
Farren, Matthew R; Mace, Thomas A; Geyer, Susan et al. (2016) Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. Clin Cancer Res 22:2565-74
Noonan, Anne M; Farren, Matthew R; Geyer, Susan M et al. (2016) Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Mol Ther 24:1150-8
Markowitz, Joseph; Abrams, Zachary; Jacob, Naduparambil K et al. (2016) MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches. Onco Targets Ther 9:5931-5941
Latchana, Nicholas; Regan, Kelly; Howard, John Harrison et al. (2016) Global microRNA profiling for diagnostic appraisal of melanocytic Spitz tumors. J Surg Res 205:350-8
Markowitz, Joseph; Mal, Tapas K; Yuan, Chunhua et al. (2016) Structural characterization of NRAS isoform 5. Protein Sci 25:1069-74
Mansfield, Sara; Grießl, Marion; Gutknecht, Michael et al. (2015) Sepsis and cytomegalovirus: foes or conspirators? Med Microbiol Immunol 204:431-7
Plews, Robert L; Mohd Yusof, Adlina; Wang, Chaojie et al. (2015) A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth. J Clin Endocrinol Metab 100:E748-56
Deng, Youcai; Kerdiles, Yann; Chu, Jianhong et al. (2015) Transcription factor Foxo1 is a negative regulator of natural killer cell maturation and function. Immunity 42:457-70
Lustberg, Mark E; Pelletier, Ronald P; Porcu, Pierluigi et al. (2015) Human leukocyte antigen type and posttransplant lymphoproliferative disorder. Transplantation 99:1220-5

Showing the most recent 10 out of 56 publications